INFAI-news
infai-news-inhalt-barcode

Serialization

Implementing the EU’s Falsified Medicines Directive – new line of INFAI packaging

The EU’s Falsified Medicines Directive (2011/62/EU) has been in force since February 9, 2019. The directive is expected to protect the well-being of patients by putting an end to the criminal counterfeiting of medicine

infai-news-inhalt-logo

Current studies

INFAI is currently conducting the following clinical studies.

Study PPI; Eudra CT Number: 2017-001369-25
The Sensitivity and Specificity in Helicobacter Pylori Positive and Negative Patients with Dyspesia Taking Proton Pump Inhibitors. Sponsor: INFAI

infai-news-inhalt-logo

COVID-19

ueg

INFAI at the United European Gastroenterology (UEG) in Amsterdam 2020

INFAI will participate in the 28th UEG (United European Gastroenterology) Week, October 10-15, 2020, in Amsterdam, the Netherlands.

The exhibition will take place at RAI Amsterdam.

ehmsg

INFAI at the European Helicobacter and Microbiota Study Group (EHMSG)

INFAI at the European Helicobacter and Microbiota Study Group (EHMSG)

INFAI will be present at the European Helicobacter and Microbiota Study Group (EHMSG) – XXXIVth Workshop of the European Helicobacter and Microbiota Study Group – EHMSG 2021
Belgrade Serbia | September 16 – 18, 2021

Health Plus Care News-Beitragsbild

INFAI at HealthPlusCare in London 2020

INFAI will participate in HealthPlusCare in London UK, June 24-25, 2020.

The exhibition will take place at ExCeL London.

bsg

INFAI at the BSG Annual Meeting in Liverpool 2020

INFAI will participate in the BSG (British Society of Gastroenterology) Annual Meeting in Liverpool, UK, June 15-18, 2020.

The exhibition will be held at ACC Liverpool.

Headquarters INFAI GmbH

Riehler Straße 36
D-50668 Cologne, Germany

R&D INFAI

Universitätsstraße 136
D-44799 Bochum, Germany

Production INFAI

Niederlassung Hagen
An der Kohlenbahn 39
D-58135 Hagen, Germany

Copyright 2020 INFAI GmbH ©  All Rights Reserved